NOVOZYMES A/S SPONS.ADR 1 (F:NZM) — Stock Price
NOVOZYMES A/S SPONS.ADR 1 (F:NZM) is currently trading at €50.00 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €44.80 and €66.00. This page tracks NOVOZYMES A/S SPONS.ADR 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NZM stock market capitalisation.
NOVOZYMES A/S SPONS.ADR 1 (NZM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks NOVOZYMES A/S SPONS.ADR 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
NOVOZYMES A/S SPONS.ADR 1 Income Statement — Revenue, Profit & Earnings by Year
NOVOZYMES A/S SPONS.ADR 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €4.16 Billion | €3.83 Billion | €2.40 Billion | €2.36 Billion | €2.01 Billion |
| Cost of Revenue | €1.92 Billion | €2.02 Billion | €1.10 Billion | €1.07 Billion | €850.85 Million |
| Gross Profit | €2.24 Billion | €1.81 Billion | €1.30 Billion | €1.29 Billion | €1.16 Billion |
| Research & Development | €463.80 Million | €413.20 Million | €270.70 Million | €268.56 Million | €270.13 Million |
| SG&A | €911.80 Million | €765.50 Million | €446.10 Million | €432.56 Million | €375.81 Million |
| Total Operating Expenses | €3.27 Billion | €3.17 Billion | €1.79 Billion | €1.76 Billion | €1.49 Billion |
| Operating Income | €882.60 Million | €659.00 Million | €610.90 Million | €594.29 Million | €522.37 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €68.30 Million | €76.40 Million | €23.10 Million | €13.69 Million | €13.71 Million |
| Income Before Tax | €743.40 Million | €417.10 Million | €524.70 Million | €611.47 Million | €527.61 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €583.60 Million | €305.80 Million | €405.90 Million | €493.36 Million | €423.00 Million |
NOVOZYMES A/S SPONS.ADR 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes NOVOZYMES A/S SPONS.ADR 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €16.35 Billion | €15.20 Billion | €3.81 Billion | €3.76 Billion | €3.33 Billion |
| Total Current Assets | €1.98 Billion | €1.88 Billion | €1.27 Billion | €1.24 Billion | €1.05 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €20.30 Million | €4.00 Million | €5.40 Million | €10.74 Million | €10.08 Million |
| Net Receivables | €716.50 Million | €665.60 Million | €496.70 Million | €463.57 Million | €396.38 Million |
| Inventory | €772.20 Million | €720.60 Million | €486.70 Million | €510.41 Million | €402.30 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €6.19 Billion | €5.61 Billion | €265.00 Million | €269.36 Million | €271.60 Million |
| Total Liabilities | €5.49 Billion | €4.02 Billion | €1.88 Billion | €1.85 Billion | €1.69 Billion |
| Total Current Liabilities | €2.74 Billion | €1.09 Billion | €972.70 Million | €934.52 Million | €762.78 Million |
| Long-term Debt | — | €1.53 Billion | €581.32 Million | €485.71 Million | €494.40 Million |
| Net Debt | — | €1.52 Billion | €839.20 Million | €724.21 Million | €637.73 Million |
| Total Stockholder Equity | €10.86 Billion | €11.18 Billion | €1.88 Billion | €1.86 Billion | €1.59 Billion |
| Retained Earnings | €11.16 Billion | €11.03 Billion | €1.85 Billion | €1.75 Billion | €1.52 Billion |
NOVOZYMES A/S SPONS.ADR 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how NOVOZYMES A/S SPONS.ADR 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €1.22 Billion | €1.02 Billion | €557.10 Million | €537.65 Million | €546.17 Million |
| Capital Expenditures | €470.80 Million | €359.80 Million | €275.80 Million | €387.87 Million | €166.73 Million |
| Free Cash Flow | €750.70 Million | €660.10 Million | €281.30 Million | €149.78 Million | €379.44 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €-402.70 Million | €249.80 Million | €383.20 Million | €204.67 Million | €197.12 Million |
| Stock-Based Compensation | €20.40 Million | €28.80 Million | €20.30 Million | €17.04 Million | €10.49 Million |
| Depreciation | €574.80 Million | €544.10 Million | €186.40 Million | €195.55 Million | €184.75 Million |
| Change in Cash | €3.90 Million | €117.00 Million | €17.40 Million | €11.27 Million | €-36.44 Million |
NOVOZYMES A/S SPONS.ADR 1 Earnings History — EPS Actual vs. Analyst Estimates
Track NOVOZYMES A/S SPONS.ADR 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 20, 2026 | — | — | — |
| Feb 25, 2026 | — | — | — |
| Aug 21, 2025 | — | — | — |
| May 01, 2025 | — | — | — |
| Feb 26, 2025 | — | — | — |
| Jan 26, 2023 | 3.18 | 2.79 | +13.98% |
| Nov 03, 2022 | 4.14 | 4.55 | -9.01% |
| Aug 11, 2022 | 2.90 | 2.74 | +5.84% |